Each year, an estimated 3.6 million episodes of RVGE occur among the 23.6 million children under 5 years of age in the European Union.1 Yet early vaccination can provide a high degree of protection for infants before the peak incidence of the disease.
Prof. Dr. Timo Vesikari, University of Tampere, Finland, lead author for the European recommendations commented, “Rotavirus affects almost all young children causing severe diarrhoea and vomiting. In the most severe cases, infants may need to be hospitalised. This causes a considerable burden on hospitals where it can spread rapidly through paediatric wards. We convened a group of experts to address the rotavirus issue and have concluded that to effectively reduce the burden of rotavirus gastroenteritis in Europe, universal vaccination of infants is recommended. The vaccines available are effective, have a good safety profile and can fit in with existing national vaccine schedules.”
“This recommendation for universal vaccination against rotavirus is very good news for European infants, their parents and hospitals,” said Jean Stéphenne, president of GSK Biologicals. “Rotavirus vaccination can provide a high degree of protection against rotavirus disease and its distressing symptoms that many children suffer. Fortunately, not many children die in Europe from rotavirus infection, but the burden on healthcare resources needed in treating outbreaks of the disease is very high and the vaccine will resolve major issues for paediatric hospitals.”
Rotavirus is the primary cause of acute gastroenteritis (diarrhoea and vomiting) leading to hospitalisation of infants and young children. New evidence presented today at the ESPID annual meeting shows that the burden of disease may be even higher than previously described. A study conducted in French, German, Italian, Spanish and UK hospitals investigated the burden of RVGE in children under 5 years of age over a 19-month period.2 The results show that rotavirus accounts for 56.2% of hospitalisations due to acute gastroenteritis. RVGE is more common in younger children, with a majority of cases occurring in children under 2 years and 18% of cases occurring in infants less than 6 months of age.2 Previous studies have reported that the duration of hospitalisation is longest in the youngest infants, particularly those who are under 4 months of age.3
Vaccination is the most effective way to provide a high level of protection for young children against RVGE.4,5 New data announced at the ESPID congress show that Rotarix™ provides sustained protection in children against RVGE up to the age of 2 years.6 Given in a convenient two-dose schedule, the oral vaccine offers early protection, before the peak incidence of the disease at 6-24 months.7 Rotarix™ prevents 96% of hospitalisations due to RVGE and reduces the need for medical attention by 84%.6 Principle investigator, Prof. Dr. Timo Vesikari, commented, “The new data substantiate the evidence for Rotarix™ showing that the vaccine’s efficacy is proven over the first two years of life which is the most vulnerable period to suffer from severe rotavirus gastroenteritis.”
Luke Willats | alfa
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences